http://www.reportbuyer.com/rss.htmlStay ahead of the competition with our catalogue of Prescription Drug market reports. Includes data on Europe, UK, USA, Asia and other global markets.en-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/distribution_patient_support_speciality_medicines_europe.htmlSpeciality medicines (specialty in the US) have become one of the main drivers of pharmaceutical industry growth. High tech, 'high touch' products with premium prices targeted at chronic, complex diseases, often requiring special storage and handling, with help with dosage administration, close monitoring and ongoing support for the patient needed. Manufacturers of speciality medicines seek a competitive advantage through distribution optimisation, including responsive, efficient and cost effective logistics, better management of the business risk, optimum stockholding, high quality information feedback, stock tracking, and prevention of diversion/counterfeits. 09b230975b347af4d65f140b73721c7cMon, 21 Sep 2009 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/chinese_markets_anti_tumor_drugs.htmlChina's demand for Anti-Tumor Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. 3bf7d4a355da588587f99834c9266e6fWed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/chinese_markets_central_nervous_system_disorder_drugs.htmlChina's demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. e4e6d6487abe672784b641c5e358a7b5Wed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/pharmaceutical_preparation_manufacturing_industry_u_s_its_international_trade.htmlThe Pharmaceutical Preparation Manufacturing Industry report is the most comprehensive market research report available on this industry. It provides the most updated data and analysis on the industry's key financial data, cost and pricing, competitive landscape, industry structure, and trends and opportunities. Over the past 3 years, the industry has shown a strong growth in exports, at approximately 11% constant annual growth. 88b298befec11b4339746c47db839b0eWed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/chinese_markets_respiratory_drugs.htmlChina's demand for Respiratory Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. f3effbe8c93299d29e15119360fa68aaWed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/medicinal_botanical_manufacturing_industry_u_s_its_international_trade.htmlThe just published Medicinal and Botanical Manufacturing Industry report is the comprehensive market research guide on the industry. Its provides the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current economic recession. In 2008, the value of imported products within this industry into the U. a8c363b987b530469d40601c4dcd98ebWed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/prescription_drugs_1.htmlThis report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following therapeutic class - Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents, and Others. The report provides separate comprehensive analytics for the US Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. 9ec126670c1a56851093858e9e498577Tue, 07 Jul 2009 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/north_american_western_europe_oral_solid_drug_dosage_excipients_markets.htmlThis research service discusses trends and market metrics of the excipients market. . 83609243686fcb854c27d3b7be52b655Sat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/report_chinas_oral_contraceptive_drugs_industry.htmlOral contraceptive drug has two major components: progesterone and estrogen, which achieve contraception by taking effects on physiology. Through detailed data analysis, this article is to show China's utilization rate of oral contraceptive drug is considerably lower than that in developed country, and is of low total utilization rate, but with a huge number of users absolutely. As a part of the . 93f80f649761dd827beda115bc3dfc0fTue, 05 May 2009 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/global_antivirals_market_analysis_forecasts_2008_2023.htmlInvestors are turning their attention to antiviral drug discovery because there is a renewed recognition of the promising opportunities in this $20bn market Twenty years from the inception of focused antiviral drug research, there are 8 blockbuster drugs currently on the market Its double-digit growth makes it a standout segment within the general anti-infective therapeutic class You should be maximizing your opportunities in this market The opportunities for success are there now, you should capitalize on them immediately. The key driver of the market is the rapid development of resistance to existing therapies by the evolving viruses The constant need to update the pipeline fuels your investigative and commercial interest in this market - so you must act on this today This report - Global Antivirals Market, 2008-2023 - analyses the global antiviral market comprehensively, outlining where you should aim your future developments to guarantee success The analyses tackle different aspects of the market, including the leading therapeutic classes, leading antiviral products, key industrial players as partners and financial prospects and opportunities The report also delivers in-depth predictions concerning how the market will develop from present until 2023. Global Antivirals Market, 2008-2023 examines the market for antivirals critically, through comprehensive primary and secondary research In addition to consultation with experts in the industry, this research involved a detailed study of policy documents, industrial reports and relevant news Essentially, visiongain also applied unique in-house techniques such as our developed financial forecasting, SWOT analyses and qualitative projections which are unavailable elsewhere The result is a comprehensive market-focused study with detailed financial analyses and uniquely informed opinion on the future of the antivirals market. 00b1b899f404bd09013bb8cd2975e8e6Tue, 09 Sep 2008 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/erythropoietin_epo.htmlErythropoiesis Stimulating Agents (ESA) Product description  The Competitive Intelligence Report Erythropoiesis Stimulating Agents (ESA) as of July 2008 in its 4th edition provides information on the market size of erythropoietin products in 2007, an overview on existing first and second generation epoetin products on the market, a compilation of first generation erythropoietin products in off-patent countries, and a competitor analysis in the development pipeline of biosimilars (biogenerics, follow-on biologics / FoBs) of erythropoietin (EPO) and of next generation erythropoiesis stimulating agents (ESAs). After the approval of the first biosimilar versions of epoetin in the European Union and of the first next generation, long-acting EPO product (Mircera), the competitive situation in the pipeline of new erythropoiesis stimulating agents (ESAs) has considerably changed in favour of next generation ESAs with improved features compared to epoetins. A wide spectrum of biologics and of small molecules are under development. f3c70b37559af9ad786d1f450800b39dMon, 07 Jul 2008 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/snapshots_us_prescription_pharmaceuticals_2008.htmlSnapdata's Snapshots US Prescription Pharmaceuticals 2008 provides 2007 year-end market size data, with 2008 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US prescription pharmaceuticals market and covers branded and generic prescription medication. Market value is based on sales. 2ddd7ffb80e2dd4c9de8dec178da9efcMon, 07 Jul 2008 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/orphan_drugs_europe.htmlIn order to raise public awareness, 29 February 2008 was dedicated the first European rare disease day ('a rare day for very special people'), but European payers need no reminding of the significance of rare disease treatments, generally known as orphan drugs. Eight years earlier, EU Regulation 141/2000 was enacted to encourage R&D in rare diseases and increase orphan drug output. By any standard the Regulation has been a major success. d6f8e2531e814dccb251966faa76504eTue, 15 Apr 2008 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/world_market_prescription_generic_drugs.htmlGenerics, so long the force that has shaken up the branded pharmaceutical industry, is now facing its own challenges as an industry. While growth indications are strong, there are challenges for generic companies. In the next two years, consolidation will most likely rise; the sector is expected to be rocked by increased competition from companies in Eastern Europe, India and China, as well as brand name companies seeking to protect their franchises by moving into generics. 09e6f1eb1e5d9235d1a99ae29ee238eaTue, 01 Apr 2008 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/china_anesthesia_apparatus_market_report.htmlNote: This report is for pre-sale and available within five working days after ordering China had an annual growth rate of 15% to 18% in its sales of medical apparatus in the past ten years. In 2005, China's total sales of medical apparatus exceeded CNY73 billion. In 2006, the total profit of the entire China's medical machinery industry rose 30. 4c0c0f5e8376d45ea2f7c4834d53e660Tue, 01 Apr 2008 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/antipsychotics_market_insight_analysis_2008.htmlThe total antipsychotics market revenue in 2006 was $18. 1bn. Visiongain predicts that total revenues in the antipsychotics market will peak to $18. bbf4a08e7df80ce33a332b4b0dfa1391Tue, 19 Feb 2008 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/global_pharmaceutical_markets.htmlStudy Goals And Objectives This Study Examines World Pharmaceutical Markets And Provides Pertinent Information About Sales And Production Of Pharmaceutical Products, As Well As Information About National Healthcare Systems And Drug Pricing Policies. The Report Covers 24 Countries In Detail And Provides Links To Relevant Information. There Are Also Profiles Of Larger Pharmaceutical And Biotechnology Companies, Complete With Revenue Histories. 3bb873f17af6944f1bdb9b6850d27b07Sat, 05 Jan 2008 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/world_market_prescription_cardiovascular_drugs.htmlAs one of the most competitive pharmaceutical markets, keeping track of the cardiovascular drug market can be a difficult undertaking. The range of therapeutic options available to physicians has expanded significantly in the past few years, and will continue to increase with a robust pipeline. Kalorama's 2nd edition of The World Market for Cardiovascular Drugs Market is designed to steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. 713010a1d7721a1fb3be893f4249b1b0Thu, 01 Nov 2007 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/china_lithium_carbonate_market_forecast_report_2008_2010.html Lithium is widely used in the battery industry, ceramic industry, glass industry, aluminum industry, lubricant, refrigeration, nuclear industry, optical electric industry, etc newly emerged fields. In the field of lithium application in 2006, the ratios of battery industry, lubricant and ceramic industry amounted to 21. 4%, 16. 4ef5301b40d439ebc13b13c42c9317efSat, 01 Sep 2007 12:00:00 GBPharma & Healthcare/Prescription Drugshttp://www.reportbuyer.com/pharma_healthcare/prescription_drugs/blockbuster_drugs_2006_executive_overview.htmlQuickly review the top 10 world's best selling pharmaceutical products in 2006 with this free report. Each blockbuster drug has the following detail: Target / Mechanism of Action Class of Compound Company Therapeutic Area Indication 1st approval 2006 sales (mln) vs. previous year (%) For a more detailed review of blockbusters Data for this complied by La Marie. 9f538d4f8787f8fee6dfbfaf72ce86d2Tue, 21 Aug 2007 12:00:00 GBPharma & Healthcare/Prescription Drugs